Widening of Access: rosuvastatin removal of Special Authority

From 1 October 2026, the statin rosuvastatin will no longer require a Special Authority for funded access. This means it will be open listed and may be prescribed as a funded medicine to any New Zealander where clinically appropriate.

You can read the notification on the Pharmac website here 

Please share this information:

Please share this information with your colleagues and within your networks.

If you have any questions regarding this supply issue, please contact enquiry@pharmac.govt.nz.

Ngā mihi nui,

Pharmac | Te Pātaka Whaioranga | P: +0800 660 050| www.pharmac.govt.nz